| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
We investigated if TNF-alpha antagonist, etanercept is useful for functional recovery in the olfactory system following injury. We made a model of severe injury by performing olfactory nerve transection using a rigid stainless steel blade in transgenic (OMP-tau-lacZ) mice. Etanercept was injected intraperitoneally just after the nerve transection. Histological assessment of recovery within the olfactory bulb was made at 5, 14, 42 and 70 days after injury. X-gal staining was used to label the degenerating and regenerating olfactory nerve fibers and immunohistochemical staining to detect the presence of reactive astrocytes and macrophages. Etanercept-injected animals showed significant smaller areas of injury-associated tissue, less astrocytes and macrophages, and an increase in regenerating nerve fibers in a dose-dependent manner. These findings suggest that TNF-alpha antagonist can be useful as a therapeutic drug for olfactory dysfunction by head injury.
|
